AHA summary of Pfizer COVID-19 vaccine EUA
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.
The summary covers dosing, storage and handling, preparation, and contraindications and adverse reactions. View the AHA Special Bulletin and review AHA resources on this and other COVID-19 vaccines and treatments.
Also over the weekend, the Centers for Disease Control and Prevention formally recommended the vaccine’s use for patients age 16 and older
Related News Articles
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…